Authors' reply to Turner and colleagues
BMJ
.
2014 Sep 9:349:g5441.
doi: 10.1136/bmj.g5441.
Authors
I Abubakar
1
,
S Sridhar
2
,
M Eisenhut
3
,
A Roy
4
,
R J Harris
4
,
L C Rodrigues
5
,
P Mangtani
5
,
I Adetifa
6
,
A Lalvani
2
Affiliations
1
Centre for Infectious Disease Epidemiology and MRC Clinical Trials Unit, University College London, London, UK
[email protected]
.
2
Tuberculosis Research Centre, Respiratory Infections Section, National Heart and Lung Institute, Imperial College London, London, UK.
3
Luton and Dunstable University Hospital, NHS Foundation Trust, Luton, UK.
4
Centre for Infectious Disease Surveillance and Control, Public Health England, London, UK.
5
London School of Hygiene and Tropical Medicine, London, UK.
6
Medical Research Council, Fajara, Gambia.
PMID:
25209583
DOI:
10.1136/bmj.g5441
No abstract available
Publication types
Letter
Comment
MeSH terms
BCG Vaccine*
Humans
Mycobacterium tuberculosis / immunology*
Tuberculosis / prevention & control*
Substances
BCG Vaccine
Grants and funding
08/16/01/DH_/Department of Health/United Kingdom